155 related articles for article (PubMed ID: 37705050)
41. Late-onset posttransplant Epstein-Barr virusrelated lymphoproliferative disease after cord blood transplantation for chronic active Epstein Barr virus infection: A case report.
Yamamoto M; Shindo M; Funayama T; Sumi C; Saito T; Toki Y; Hatayama M; Imadome KI; Mizukami Y; Okumura T
Medicine (Baltimore); 2022 Mar; 101(12):e29055. PubMed ID: 35357349
[TBL] [Abstract][Full Text] [Related]
42. Identification of rare Epstein-Barr virus infected memory B cells and plasma cells in non-monomorphic post-transplant lymphoproliferative disorders and the signature of viral signaling.
Shaknovich R; Basso K; Bhagat G; Mansukhani M; Hatzivassiliou G; Murty VV; Buettner M; Niedobitek G; Alobeid B; Cattoretti G
Haematologica; 2006 Oct; 91(10):1313-20. PubMed ID: 17018379
[TBL] [Abstract][Full Text] [Related]
43. Expert Consensus on the Characteristics of Patients with Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease (EBV
Chaganti S; Barlev A; Caillard S; Choquet S; Cwynarski K; Friedetzky A; González-Barca E; Sadetsky N; Schneeberger S; Thirumalai D; Zinzani PL; Trappe RU
Adv Ther; 2023 Mar; 40(3):1267-1281. PubMed ID: 36681739
[TBL] [Abstract][Full Text] [Related]
44. Molecular epidemiology of EBNA-1 substrains of Epstein-Barr virus in posttransplant lymphoproliferative disorders which have infrequent p53 mutations.
Greiner TC; Abou-Elella AA; Smir BN; Orazi A; Hinrichs S; Anderson J; Gross T; Bierman P; Hauke R
Leuk Lymphoma; 2000 Aug; 38(5-6):563-76. PubMed ID: 10953978
[TBL] [Abstract][Full Text] [Related]
45. [Epstein Barr viral load monitoring in mononuclear lymphocytes and serum of renal transplant recipients using a quantitative PCR protocol].
Merlino C; Giacchino F; Bergallo M; Bonello F; Bollero C; Segoloni GP; Cavallo R
G Ital Nefrol; 2003; 20(2):170-5. PubMed ID: 12746803
[TBL] [Abstract][Full Text] [Related]
46. Characterization of Epstein-Barr virus-infected B cells in patients with posttransplantation lymphoproliferative disease: disappearance after rituximab therapy does not predict clinical response.
Yang J; Tao Q; Flinn IW; Murray PG; Post LE; Ma H; Piantadosi S; Caligiuri MA; Ambinder RF
Blood; 2000 Dec; 96(13):4055-63. PubMed ID: 11110673
[TBL] [Abstract][Full Text] [Related]
47. Epstein-Barr virus-associated pneumonia in patients with post-transplant lymphoproliferative disease after hematopoietic stem cell transplantation.
Liu QF; Fan ZP; Luo XD; Sun J; Zhang Y; Ding YQ
Transpl Infect Dis; 2010 Aug; 12(4):284-91. PubMed ID: 20345506
[TBL] [Abstract][Full Text] [Related]
48. Evidence of Epstein-Barr virus heterogeneous gene expression in adult lung transplant recipients with posttransplant lymphoproliferative disorder.
Zaffiri L; Frankel C; Bush EJ; Neely ML; Pavlisko EN; Mokrova IL; Luftig MA; Palmer SM
J Med Virol; 2021 Aug; 93(8):5040-5047. PubMed ID: 33704812
[TBL] [Abstract][Full Text] [Related]
49. The value of EBV DNA in early detection of post-transplant lymphoproliferative disorders among solid organ and hematopoietic stem cell transplant recipients.
Wareham NE; Mocroft A; Sengeløv H; Da Cunha-Bang C; Gustafsson F; Heilmann C; Iversen M; Kirkby NS; Rasmussen A; Sørensen SS; Lundgren JD;
J Cancer Res Clin Oncol; 2018 Aug; 144(8):1569-1580. PubMed ID: 29804164
[TBL] [Abstract][Full Text] [Related]
50. Epstein-Barr virus-related post-transplant lymphoproliferative disorder in solid organ transplant recipients.
San-Juan R; Comoli P; Caillard S; Moulin B; Hirsch HH; Meylan P;
Clin Microbiol Infect; 2014 Sep; 20 Suppl 7():109-18. PubMed ID: 24475976
[TBL] [Abstract][Full Text] [Related]
51. Normalized quantification by real-time PCR of Epstein-Barr virus load in patients at risk for posttransplant lymphoproliferative disorders.
Jabs WJ; Hennig H; Kittel M; Pethig K; Smets F; Bucsky P; Kirchner H; Wagner HJ
J Clin Microbiol; 2001 Feb; 39(2):564-9. PubMed ID: 11158107
[TBL] [Abstract][Full Text] [Related]
52. Adapted treatment of Epstein-Barr virus infection to prevent posttransplant lymphoproliferative disorder after heart transplantation.
Choquet S; Varnous S; Deback C; Golmard JL; Leblond V
Am J Transplant; 2014 Apr; 14(4):857-66. PubMed ID: 24666832
[TBL] [Abstract][Full Text] [Related]
53. Lymphoproliferative disease after allogeneic stem cell transplantation--pre-emptive diagnosis by quantification of Epstein-Barr virus DNA in serum.
Aalto SM; Juvonen E; Tarkkanen J; Volin L; Ruutu T; Mattila PS; Piiparinen H; Knuutila S; Hedman K
J Clin Virol; 2003 Dec; 28(3):275-83. PubMed ID: 14522066
[TBL] [Abstract][Full Text] [Related]
54. Primary Epstein-Barr virus infection, seroconversion, and post-transplant lymphoproliferative disorder in seronegative renal allograft recipients: a prospective cohort study.
Hosseini-Moghaddam SM; Alhomayeed B; Soliman N; Weir MA; House AA
Transpl Infect Dis; 2016 Jun; 18(3):423-30. PubMed ID: 27016725
[TBL] [Abstract][Full Text] [Related]
55. Biological Difference Between Epstein-Barr Virus Positive and Negative Post-transplant Lymphoproliferative Disorders and Their Clinical Impact.
Ferla V; Rossi FG; Goldaniga MC; Baldini L
Front Oncol; 2020; 10():506. PubMed ID: 32457824
[TBL] [Abstract][Full Text] [Related]
56. Comparative analysis of post-transplant lymphoproliferative disorders after solid organ and hematopoietic stem cell transplantation reveals differences in the tumor microenvironment.
Overkamp M; Granai M; Bonzheim I; Steinhilber J; Schittenhelm J; Bethge W; Quintanilla-Martinez L; Fend F; Federmann B
Virchows Arch; 2021 Jun; 478(6):1135-1148. PubMed ID: 33324999
[TBL] [Abstract][Full Text] [Related]
57. Evaluation of use of Epstein-Barr viral load in patients after allogeneic stem cell transplantation to diagnose and monitor posttransplant lymphoproliferative disease.
Gärtner BC; Schäfer H; Marggraff K; Eisele G; Schäfer M; Dilloo D; Roemer K; Laws HJ; Sester M; Sester U; Einsele H; Mueller-Lantzsch N
J Clin Microbiol; 2002 Feb; 40(2):351-8. PubMed ID: 11825941
[TBL] [Abstract][Full Text] [Related]
58. EBV PCR in the diagnosis and monitoring of posttransplant lymphoproliferative disorder: results of a two-arm prospective trial.
Tsai DE; Douglas L; Andreadis C; Vogl DT; Arnoldi S; Kotloff R; Svoboda J; Bloom RD; Olthoff KM; Brozena SC; Schuster SJ; Stadtmauer EA; Robertson ES; Wasik MA; Ahya VN
Am J Transplant; 2008 May; 8(5):1016-24. PubMed ID: 18312608
[TBL] [Abstract][Full Text] [Related]
59. A Case of Central Nervous System Post-Transplant Lymphoproliferative Disorder Following Haploidentical Stem Cell Transplantation in a Patient With Acute Lymphoblastic Leukemia.
Zhu H; Li Q; Liu Y; Feng X; Deng Q
Cell Transplant; 2022; 31():9636897221117532. PubMed ID: 35979928
[TBL] [Abstract][Full Text] [Related]
60. Epidemiology of posttransplantation lymphoproliferative disorder in adult renal transplant recipients.
Morton M; Coupes B; Roberts SA; Klapper PE; Byers RJ; Vallely PJ; Ryan K; Picton ML
Transplantation; 2013 Feb; 95(3):470-8. PubMed ID: 23222821
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
